Chemotherapy plus Vandetanib or Chemotherapy Alone in Advanced Non-small Cell Lung Cancer: A Meta-analysis of Four Randomised Controlled Trials

Although similar in overall survival, chemotherapy plus vandetanib showed particular advantages over chemotherapy alone in terms of progression-free survival and overall response rate. The toxicity was comparable between the two groups. Therefore, chemotherapy plus vandetanib might be a safe and valid therapeutic option for advanced NSCLC patients.